Please assess the completion status of the following clinical trial:

Trial Title: The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe stable chronic obstructive pulmonary disease~* Smoking history of 10 pack years~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 30 - 80%~* Patients must be able to use computer mouse and display~* mMRC grade\>2~Exclusion Criteria:~* Patients with a history of long QT syndrome~* Patients with Type I or uncontrolled Type II diabetes~* Patients who have had a COPD exacerbation or respiratory tract infection within 6 weeks prior to screening~* Patients with any history of asthma~* Patients with pulmonary lobectomy, lung volume reduction surgery, or lung transplantation~* Patients with concomitant pulmonary disease~* Patients requiring long term oxygen therapy (\>15 h a day)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 + placebo to tiotropium (Type: EXPERIMENTAL): Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
- Tiotropium + placebo to QVA149 (Type: ACTIVE_COMPARATOR): Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).